AIRLINK 188.03 Decreased By ▼ -1.98 (-1.04%)
BOP 11.86 Decreased By ▼ -0.05 (-0.42%)
CNERGY 7.54 Increased By ▲ 0.11 (1.48%)
FCCL 37.79 Decreased By ▼ -0.64 (-1.67%)
FFL 15.24 Increased By ▲ 0.57 (3.89%)
FLYNG 25.53 No Change ▼ 0.00 (0%)
HUBC 130.15 Decreased By ▼ -0.53 (-0.41%)
HUMNL 13.61 Increased By ▲ 0.21 (1.57%)
KEL 4.35 Decreased By ▼ -0.11 (-2.47%)
KOSM 6.17 Increased By ▲ 0.06 (0.98%)
MLCF 45.68 Decreased By ▼ -0.64 (-1.38%)
OGDC 206.43 Decreased By ▼ -2.67 (-1.28%)
PACE 6.38 Increased By ▲ 0.06 (0.95%)
PAEL 40.31 Decreased By ▼ -0.60 (-1.47%)
PIAHCLA 16.95 Decreased By ▼ -0.10 (-0.59%)
PIBTL 8.03 Increased By ▲ 0.09 (1.13%)
POWER 10.03 Increased By ▲ 0.57 (6.03%)
PPL 178.84 Decreased By ▼ -4.89 (-2.66%)
PRL 36.36 Increased By ▲ 0.88 (2.48%)
PTC 24.39 Decreased By ▼ -0.38 (-1.53%)
SEARL 103.16 Decreased By ▼ -0.22 (-0.21%)
SILK 1.07 No Change ▼ 0.00 (0%)
SSGC 36.24 Decreased By ▼ -0.03 (-0.08%)
SYM 18.23 Decreased By ▼ -0.55 (-2.93%)
TELE 8.38 Decreased By ▼ -0.04 (-0.48%)
TPLP 12.16 Increased By ▲ 0.03 (0.25%)
TRG 67.33 Decreased By ▼ -0.25 (-0.37%)
WAVESAPP 12.01 Decreased By ▼ -0.19 (-1.56%)
WTL 1.57 Increased By ▲ 0.02 (1.29%)
YOUW 3.89 Increased By ▲ 0.04 (1.04%)
BR100 11,907 Decreased By -53.1 (-0.44%)
BR30 35,554 Decreased By -354.2 (-0.99%)
KSE100 112,564 Decreased By -360.9 (-0.32%)
KSE30 35,094 Decreased By -217.6 (-0.62%)

KARACHI: BF Biosciences IPO’s book building phase will be held on 25th and 26th September where high net worth individuals and institutional investors will subscribe to 100 per cent of the issue size.

BF Biosciences, a leader in the biotech pharmaceuticals sector in Pakistan, is set to raise between Rs 1.38 billion and Rs1.93 billion to expand its key product lines and obtain export certifications.

The floor price for the issue has been set at Rs 55 per share through a 100 percent book building process.

BF Biosciences plans to raise up to Rs1.93bn through IPO

The unsubscribed shares, if any, of the general subscription portion would be allocated to the successful bidders of the book building portion on a pro-rata basis.

The issuer will utilize any additional funds raised above the floor price in managing its additional requirements for capex and working capital needs.

BF Biosciences has estimated that the maximum strike price for the IPO may climb to Rs 77 per share that would increase the funds raised to Rs 1.93 billion.

This strategic initiative is expected to drive significant growth in both the company’s top line and profitability as company has already completed a brownfield expansion and IPO will also help the company to manage working capital needs of the aforesaid expansion.

Arif Habib Limited has been appointed as a lead manager and book runner to the issue.

Copyright Business Recorder, 2024

Comments

Comments are closed.